Alligator contracts BioInvent for process development and cGMP manufacturing of the immuno-oncology drug candidate ADC-1015
Alligator Bioscience AB is a privately held Swedish biotech company developing immuno-oncology antibodies for tumor-directed immunotherapy. Alligator has contracted BioInvent for process development and cGMP manufacturing of the immuno-oncology drug candidate ADC-1015. The agreement will supply Alligator with ADC-1015 Drug Product for early clinical trials.
Alligator has a strong pipeline consisting of 5 drug candidates. ADC-1013 is an immune activating antibody directed against CD40, developed for treatment of metastatic cancer. Clinical trials in cancer patients were initiated early 2015, and ADC-1013 was later the same year out-licensed to Janssen Biotech, a Johnson & Johnson oncology company. ADC-1015 is a bispecific immune activating antibody that targets OX40 and CTLA-4. Since both OX40 and CTLA-4 are expressed on T cells in the tumor area, ADC-1015 is expected to induce strong tumor-directed immune activation. ADC-1015 has the potential to become first-in-class in this category of immune activating bispecific antibodies. In addition to ADC-1013 and ADC-1015, Alligator has three drug candidates in research phase.
For further information, please contact:
Per Norlén, CEO Alligator Bioscience AB, Office number: +46 46 2864280
Alligator discovers and develops innovative antibody based immunotherapies for the treatment of metastatic cancer. Drug Discovery and Development at Alligator spans from early research phases up to proof of concept phase I/II clinical studies in cancer patients.
In the development of new antibody-based drugs, Alligator uses its proprietary technology platforms comprising the human antibody library ALLIGATOR-GOLD® and the antibody optimization technology FIND®. Together, these technologies enable development of drug candidates with significant clinical benefits. ALLIGATOR-GOLD® is a synthetic library containing several billion distinct fully human antibodies.
Alligator was founded in 2001, is a privately held company with 35 employees and around 200 shareholders, and is located at Medicon Village, Lund, Sweden.